DOCSLIB.ORG

Plenary Program & CPDD 2004 Awards

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Plenary Program & CPDD 2004 Awards Plenary Program & CPDD 2004 Awards OP S und a y Jun e 13, 2 004 S a n Ge ro n im o Ba llr o om , Ca ribe Hil t o n S a n Jua n , P uert o R ico Previous Award Winners Plenary Session Nathan B. Eddy Joseph Cochin Young Memorial Award Investigator Award 8:00 • Welcome 1974 • Maurice Seevers 1987 • Michael Bozarth Chris-Ellyn Johanson, President, CPDD 1975 • Harris Isbell 1988 • Frank Porreca 1976 • Abraham Wikler 1989 • Errol B. De Souza 8:30 • Report from National Institute on Drug Abuse 1977 • William Martin 1990 • Thomas Kosten 1978 • Hans Kosterlitz 1991 • Richard Rothman Nora D. Volkow, Director, NIDA 1979 • E. Leong Way 1992 • Jeffrey M. Witkin 1980 • Avram Goldstein 1993 • Stephen Higgins 9:00 • Presentation of the Media Award to 1981 • Everette May 1994 • Richard W. Foltin Peter Reuter 1982 • Vincent Dole 1995 • Warren K. Bickel Marie Nyswander 1996 • Toni Shippenberg Introduction by Wallace Pickworth 1983 • Eric Simon 1997 • Lisa H. Gold 1984 • Raymond Houde 1998 • S. Stevens Negus 9:05 • Presentation of the J. Michael Morrison Award 1985 • Louis Harris 1999 • Sari Izenwasser to Ronald Brady 1986 • Harold Kalant 2000 • Leslie Amass Introduction by George E. Woody 1987 • Clifton K. Himmelsbach Sharon Walsh 1988 • Albert Herz 2001 • S. Barak Caine 9:10 • Presentation of the Joseph Cochin Young 1989 • Leo E. Hollister 2002 • Laura Sim-Selley 1990 • Charles Schuster 2003 • Andrew Coop Investigator Award to Sandra D. Comer 1991 • Phillip S. Portoghese J. Michael Morrison Introduction by Herbert Kleber Akira E. Takemori Award 1992 • Joseph V. Brady 1986 • Edward C. Tocus 9:15 • Presentation of the Mentorship Award to 1993 • Lee N. Robins 1988 • Marvin Snyder E. Leong Way 1994 • Jerome H. Jaffe 1990 • Arthur E. Jacobson Introduction by Horace Loh 1995 • Herbert D. Kleber 1992 • Hans Halbach 1996 • Griffith Edwards 1993 • Beny Primm 1997 • Martin W. Adler *Special Award 9:20 • Presentation of the Nathan B. Eddy Award to 1998 • John W. Lewis 1995 • Jack D. Blaine James H. Woods 1999 • Mary Jeanne Kreek 1997 • Rao Rapaka Introduction by Kenner C. Rice 2000 • William L. Dewey 1999 • Roy W. Pickens 2001 • Kenner C. Rice 2001 • Roger Brown 9:30 • Nathan B. Eddy Award Lecture: 2002 • Horace H. Loh 2003 • Richard L. Hawks Monkeys, Michigan, Me, and Mu 2003 • Charles P. O’Brien Media Award Mentorship Award 1990 • Katie McCabe James H. Woods, University of Michigan Medical School 2000 • Robert L. Balster 1992 • James Burke 2001 • James H. Woods 1998 • Riester Robb 10:15 • Presidents Lecture: 2002 • Conan Kornetsky 2000 • Sean Clarkin Stress and Alcoholic Phenotype 2003 • Charles R. Shuster Carlos Davila Rinaldi Distinguished Kathleen Grant, Wake Forest University 2001 • Michael Massing School of Medicine Service Award 2002 • David T. Courtwright 1994 • Richard A. Millstein 2003 • Addiction Studies 2002 • Alan I. Leshner Program for Journalists 2003 • Francis Vocci, Jr. Charles O’ Keeffe Nathan B. Eddy Award James H. Woods, PhD Professor, University of Michigan Medical School Dr. Woods was born in Louisa, Kentucky. When he was 15, his family moved to an Ohio farm. He received his undergraduate degree in Commerce and Psychology from Ohio University and went to the University of Virginia to obtain his PhD in Psychology. He took a position in Pharmacology at the University of Michigan in the laboratory of Charles Schuster (who was to become the 1990 Eddy Awardee). Dr. Woods is currently a Professor of Pharmacology and Psychology there. He has conducted research in primates on narcotics, a speciality that was initiated at Michigan by the first Eddy Awardee, Dr. Maurice Seevers, at the instigation of Nathan B. Eddy. The primate facility has been an outstanding training resource for graduate and postgraduate researchers. Dr. Woods received the CPDD Outstanding Mentor Award in 2001. He has served on the Board of Directors of the CPDD, and he currently chairs the Drug Evaluation Committee of the College. Dr. Woods has published over 300 articles on various subjects related to drug abuse, and he has been recognized as a highly cited researcher in Pharmacology by the Institute for Scientific Information. Mentorship Award Media Award Peter Reuter, PhD E. Leong Way, PhD Professor, School of Public Affairs and Department of Criminology, Emeritus Professor of Pharmacology University of Maryland University of California, San Francisco Editor, Journal of Policy Analysis and Management During the interval between 1949 and 1987, perhaps some 70 Dr. Reuter received his PhD in Economics from Yale. From 1981 to 1993, collaborators, including graduate, medical and in residence students, He was a Senior Economist in the Washington office of the RAND postdoctorals as well as mature scholars, domestic and foreign, passed Corporation. In 1989, he founded RAND’s Drug Policy Research Center, through Dr. Way's laboratory. The numbers include an academic family a multi-disciplinary research program begun with funding from a of five generations, a father and son and three Nathan B. Eddy awardees. number of foundations. He directed it from 1989-1993. His early research Together they generated approximately 400 publications related to basic focused on the organization of illegal markets and resulted in the aspects of substance abuse concerned with opiate pharmacokinetics, publication of Disorganized Crime: The Economics of the Visible Hand (MIT tolerance and physical dependence. The laboratory findings often Press, 1983), which won the Leslie Wilkins award as most outstanding provided concepts that gave meaning to clinical observations. An book of the year in criminology and criminal justice. Since 1985 most of explanation of the selective pharmacodynamic characteristics of heroin his research has dealt with alternative approaches to controlling drug and morphine was attained by comparative and developmental studies problems, both in the United States and Western Europe. His book (with on their disposition and integrating their physical and chemical Robert MacCoun) entitled Drug War Heresies: Learning from Other Places, properties with host considerations related to species, age, blood/brain Times and Vices (Cambridge University Press) appeared in August 2001. barrier maturation and mode of drug administration. Extensive in vivo Dr. Reuter was a member of the National Research Council Committee on and in vitro investigations on morphine tolerance and physical Law and Justice from 1997-2002. He served on the Institute of Medicine dependence development established that the two phenomena have a Committee on the Federal Regulation of Methadone (1992-1994) and the common underlying neurophysiologic basis. Dr. Way’s many IOM panel on Assessing the Scientific Base for Reducing Tobacco-Related publications include Endogenous and Exogenous Opiate Agonist and Harm (2000). He was on the Board of Directors of CPDD from 1994-1998 Antagonists (editor), New Concepts in Pain (editor), Fundamentals of Drug and was also a member of the Office of National Drug Control Policy’s Metabolism and Drug Disposition (co-editor with B. Lu Du and G. Mandel) Committee on Data, Research and Evaluation from 1996-2002. The and a monograph, Biologic Disposition of Morphine and Its Surrogates (with Attorney General appointed him as one of five non-governmental T. K. Adler), as well as scientific review and original articles on drug members of the Interagency Task Force on Methamphetamine in 1997. He metabolism, analgesics, developmental pharmacology, drug testifies frequently before Congress and has addressed senior policy tolerance/drug dependence and Chinese medical material. After retiring, audiences in many countries. He has served as a consultant to numerous Dr. Way has been involved in reinterpreting the theories of Chinese government agencies and foreign organizations. Dr. Reuter is currently a traditional medicine that are consistent with those of contemporary Senior Economist at RAND. pharmacology. J. Michael Morrison Award Joseph Cochin Young Investigator Award Sandra D. Comer, PhD Associate Professor Ronald Brady, MD College of Physicians and Surgeons of Columbia University Medical Director Dr. Sandra Comer is an Associate Professor of Clinical Neuroscience in New York State Psychiatric Institute the Department of Psychiatry at the College of Physicians and Surgeons of Columbia University and a Research Scientist at the New York State Dr. Brady graduated from Temple University School of Medicine and Psychiatric Institute. Dr. Comer received her undergraduate degree at completed his residency in Psychiatry at The Payne Whitney Clinic in Vanderbilt University (1987) and completed her graduate training at the 1970. He engaged in private practice for five years. Vincent and Marie University of Michigan, where she received her Master of Science (1988) Dole stimulated his interest in Addiction Medicine, and he has directed and Doctorate in Philosophy (1992) degrees for her research in the The Bridge Plaza Treatment and Rehabilitation Clinic for some 30 years. laboratory of Dr. James H. Woods on the effects of opioid drugs. The clinic serves as a model for the integration of research and clinical Following graduate school, Dr. Comer completed a two-year postdoctoral activities. In addition, he has served as an advisor to the New York State fellowship at University of Minnesota, Minneapolis. There she received Drug Abuse Commission, co-authored 15 papers on various aspects of training in preclinical animal models of cocaine self-administration in methadone treatment and lectured extensively on automated dispensing. rodents and non-human primates in the laboratory of Dr. Marilyn Carroll. He invented the automated dispensing system in 1975 and has spent the In 1993, Dr. Comer began working at the Division of Substance Abuse at intervening years perfecting it. The system is currently installed in some Columbia University. Here she received training in human preclinical 700 clinics throughout the United States and Europe. Dr. Brady is Director studies under the mentorship of Dr. Marian Fischman and of Clinical Services at Bridge Plaza and participates in the training of Dr. Richard Foltin. Dr. Comer’s research focus has been on the Columbia Post Graduate Fellows in Addiction Medicine.
Load more

Recommended publications
  • Methadone and the Anti-Medication Bias in Addiction Treatment
    White, W. & Coon, B. (2003). Methadone and the anti-medication bias in addiction treatment. Counselor 4(5): 58-63. Methadone and the Anti-medication Bias in Addiction Treatment William L. White, MA and Brian F. Coon, MA, CADC An Introductory Note: This article is long overdue. Like many addiction counselors personally and professionally rooted in the therapeutic community and Minnesota model programs of the 1960s and 1970s, I exhibited a rabid animosity toward methadone and protected these beliefs in a shell of blissful ignorance. That began to change in the late 1970s when a new mentor, Dr. Ed Senay, gently suggested that the great passion I expressed on the subject of methadone seemed to be in inverse proportion to my knowledge about methadone. I hope this article will serve as a form of amends for that ignorance and arrogance. (WLW) There is a deeply entrenched anti-medication bias within the field of addiction treatment. This bias is historically rooted in the iatrogenic insults that have resulted from attempts to treat drug addiction with drugs. The most notorious of these professional practices includes: coaching alcoholics to substitute wine and beer for distilled spirits, treating alcoholism and morphine addiction with cocaine and cannabis, switching alcoholics from alcohol to morphine, failing repeatedly to find an alcoholism vaccine, employing aversive agents that linked alcohol or morphine to the experience of suffocation and treating alcoholism with drugs that later emerged as problems in their own right, e.g., barbiturates, amphetamines, tranquilizers, and LSD. A history of harm done in the name of good culturally and professionally imbedded a deep distrust of drugs in the treatment of alcohol and other drug addiction (White, 1998).
    [Show full text]
  • Evaluation of Need and Feasibility of Tuberculosis Screening in Buprenorphine Treatment Programs Ryan Schwarz
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2011 Evaluation Of Need And Feasibility Of Tuberculosis Screening In Buprenorphine Treatment Programs Ryan Schwarz Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Schwarz, Ryan, "Evaluation Of Need And Feasibility Of Tuberculosis Screening In Buprenorphine Treatment Programs" (2011). Yale Medicine Thesis Digital Library. 1593. http://elischolar.library.yale.edu/ymtdl/1593 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Evaluation of need and feasibility of tuberculosis screening in buprenorphine treatment programs A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine by Ryan Schwarz Class of 2011 Table of Contents Acknowledgements .............................................................................................................................................. 3 Declaration of Interest .......................................................................................................................................
    [Show full text]
  • Marie Nyswanders Beitrag: Der Drogenabhängige Als Patient
    SCHWERPUNKTTHEMA nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn S11 Marie Nyswanders Beitrag: Robert G. Newman Der Drogenabhängige als Patient Beth Israel Medical Center, New York, USA Zusammenfassung: Dieser Artikel schildert die besonderen Ein groûartiger Kollege, Josh von Soer Clemm von Hohenberg, Verdienste Mary Nyswanders in der Betrachtungsweise der der gebürtig aus den Niederlanden stammte, aber jahrelang Behandlung von Drogenabhängigen. Dabei spielte die Charak- in Hamburg lebte und auch dort arbeitete, hatte sein Leben terisierung des Drogenabhängigen als Patienten eine beson- der Hilfe all derer und ihrer Freunde und Angehörigen dere Rolle, nämlich in der Methadon-Erhaltungsbehandlung, gewidmet, die von Abhängigkeitserkrankungen betroffen die auf eine dauerhafte Behandlung und nicht auf vollständige sind. Ich muss gestehen, ich war sprachlos, als mich Josh und sofortige Heilung abzielt. damals anrief und mir mitteilte, dass seine jahrelangen eigenhändigen Bemühungen, Marie (die zehn Jahre zuvor Schlüsselwörter: Opiatabhängigkeit ± Ethische Probleme ± verstorben war) mit einer nach ihr zu Ehren benannten Methadon ± Substitutionsbehandlung ± Patientenbild Straûe Anerkennung zu zollen, schlieûlich von all den vielen dafür zuständigen Behörden genehmigt worden war. The Contribution of Marie Nyswander ± The Drug Addict Nirgends sonst auf der Welt gibt es eine vergleichbare as a Patient: This article describes the special contribution Anerkennung, weder für Marie noch für Vince Dole ± nicht in of Marie Nyswander's way of looking at the treatment of den USA, wo sie ihre Pionierarbeit leisteten und wo heute drug addicts. She focused on the characterization of the drug über 160000 Menschen Methadonbehandlungen erhalten; addict as a patient, namely in the methadone maintenance nicht in Hongkong, wo Heroinabhängigen seit über einem treatment, which aims at a long-lasting treatment and not at Vierteljahrhundert ein sofortiger Zugang (d.h.
    [Show full text]
  • 2019 Plenary Brochure
    Pg-12 Pg-1 Notes Plenary Program and CPDD 2019 Awardees Sunday, June 16, 2019 at 8:00 AM - 11:00 AM JW Marriott Hill Country Resort & Spa Grand Oaks Ballroom K/L/M San Antonio, Texas Plenary_2019_12_Pages_050919.indd 1 5/10/19 10:22 AM Pg-2 Pg-11 Notes NATHAN B. EDDY MEMORIAL AWARD Maxine Stitzer, Ph.D. Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine Dr. Stitzer received her Ph.D. in Psychology from the University of Michigan under mentorship of James H. Woods. She subsequently became a founding faculty member of the Behavioral Pharmacology Research Unit at Johns Hopkins University School of Medicine, a nationally recognized substance abuse research laboratory within the Department of Psychiatry. Her interests during a successful 40+ year NIDA- supported research career focused on both pharmacological and behavioral approaches to the treatment of substance use disorders including opioid, stimulant and tobacco use disorders. She is best known for her pioneering work on Contingency Management in substance abuse treatment, an approach designed to enhance motivation for positive behavior change. She provided leadership at Hopkins from 1999 – 2019 of the Mid-Atlantic Node of the National Institute on Drug Abuse Clinical Trials Network (CTN). She has been an active member of CPDD throughout her career and served on the CPDD Board of Directors from 1993 – 97 and from 2006 -10. She received the Marian Fischman Award from the College in 2003. Her research overall has advanced the understanding of substance use disorders and promoted adoption of evidence-based treatments into clinical practice.
    [Show full text]
  • Canada Archives Canada Published Heritage Direction Du Branch Patrimoine De I'edition
    "THE CHEMOPHILIC SOCIETY": ADDICTION RESEARCH AFTER THE CLASSIC PERIOD OF NARCOTIC CONTROL, 1957-1975 A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by YVAN CRAIG PRKACHIN In Partial Fulfillment of requirements for the degree of Master of Arts April, 2008 © Yvan Craig Prkachin, 2008 Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-41860-4 Our file Notre reference ISBN: 978-0-494-41860-4 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library permettant a la Bibliotheque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Plntemet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans loan, distribute and sell theses le monde, a des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, electronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in et des droits moraux qui protege cette these. this thesis. Neither the thesis Ni la these ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent etre imprimes ou autrement may be printed or otherwise reproduits sans son autorisation.
    [Show full text]
  • Justifying Drug Substitution Therapies: the Case of Methadone Treatment
    Justifying drug substitution therapies: The case of methadone maintenance treatment Jeff Ward School of Psychology Australian National University Canberra ACT 0200, Australia Email: [email protected] Paper presented at 2nd Annual Conference of the Addiction Research Centre, Trinity College, Dublin, Ireland, 26 September 2002 1 Introduction Some time ago, I was told the story of a meeting that took place in a local community, the purpose of which was to decide whether a methadone clinic should be established there. At this meeting, members of the relevant government health authority and medical practitioners wanting to establish the clinic tried to alleviate community concerns about the clinic by talking about the evidence in favour of methadone maintenance and responding to concerns raised during the meeting. Concerns were raised about the possibility of the clinic attracting more heroin users to the area, the effects on local business, the risks associated with discarded needle and syringes, and so on. After long discussion, it appeared that the majority of the audience were convinced that methadone maintenance was an effective treatment for heroin dependence and their fears were assuaged by the arguments that they had heard. Just as the meeting was drawing to a close, one member of the audience raised her hand and wanted to know if methadone was a drug just like heroin. When it was answered, somewhat reluctantly by my informant that, yes, methadone was a drug that acted in ways similar to heroin, the mood of the meeting immediately changed, and, within a short period of time, it became clear that if methadone was a drug just like heroin, then people didn’t want a methadone clinic in their community.
    [Show full text]
  • Remembering Mary Jeanne Kreek and Her Many Contributions to Addiction Science
    obituary Remembering Mary Jeanne Kreek and her many contributions to addiction science hen Dr. Mary Jeanne Kreek World Health Organization’s (WHO) list of passed away on March 27, at the most efficacious, safe, and cost-effective Wage 84, the field of addiction medicines for priority conditions3, and it science lost a true giant. Her research not has helped countless patients with opioid only paved the way for the first medication addiction toward leading healthy and treatment for opioid addiction, but also productive lives. made landmark contributions to our In the 1970s, when methadone was understanding of addiction as a brain first making inroads treating patients with disorder, the genetic factors underlying opioid addiction, the mechanisms of opioid addictive disorders, and the close links compounds’ actions in the brain were still between injection drug use and HIV. poorly understood. Opioid receptors were Kreek had been the Patrick E. and Beatrice first identified in 1973, and opioid peptides M. Haggerty Professor and Head of the were discovered in 1975. Kreek’s research Laboratory of the Biology of Addictive in her lab at The Rockefeller University Diseases at The Rockefeller University in over the following years clarified how the New York City and Senior Physician of The endogenous opioid signaling system plays a Rockefeller University Hospital. role not only in opioid addiction but also in Bitten by the science bug at an early age, addiction to alcohol and cocaine. Kreek already knew when she was a little Among her many important girl that she would go into medicine. As contributions to the field of addiction she tells it in an oral history interview for research over subsequent decades, Kreek The Rockefeller University1, she entered was the first to identify injection drug use Credit: JOSIE ANDERSON her first science fair in the sixth grade, and as the second major risk behavior (after at age 15 participated in a TV series called unprotected sex) for HIV transmission.
    [Show full text]
  • Supporting Recovery from Opioid Addiction: Community Care Best
    Supporting Recovery from Opioid Addiction: Community Care Best Practice Guidelines for Recovery-Oriented Methadone Maintenance July 2014 Supporting Recovery from Opioid Addiction: Community Care Best Practice Guidelines for Recovery-Oriented Methadone Maintenance June 2014 | Community Care Behavioral Health Organization | www.ccbh.com Contact: Marge Hanna Senior Director, Substance Use Disorder Initiatives, Community Care [email protected] | 412.454.2120 © 2014 Community Care Behavioral Health Organization Contents Executive Summary .......................................................................................................................................................... 4 I. Introduction ................................................................................................................................................................ 4 II. Background ............................................................................................................................................................... 7 III. Recovery-Oriented Methadone Maintenance (ROMM) ............................................................................................. 12 IV. Scope and Purpose ................................................................................................................................................... 13 V. Intended Audience ................................................................................................................................................... 14 VI. Limitations
    [Show full text]
  • Progress in the Development of Cost-Effective Treatment for Drug Abusers
    Progress in the Development of Cost- Effective Treatment for Drug Abusers U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Progress in the Development of Cost-Effective Treatment for Drug Abusers Editor: Rebecca S. Ashery, D.S.W. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 58 1985 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state of-the-art conferences, and integra- tive research reviews. Its dual publication emphasis is rapid and targeted dissem- ination to the scientific and professional community. Editorial Advisors Martin W. Adler, Ph.D. Temple University School of Medicine Philadelphia, Pennsylvania Sydney Archer, Ph.D. Rensselaer Polytechnic Institute Troy, New York Richard E. Belleville, Ph.D. NB Associates. Health Sciences Rockville, Maryland Gilbert J. Botvin, Ph.D. Cornell University Medical College New York, New York Joseph V. Brady, Ph.D. The Johns Hopkins University School of Medicine Baltimore, Maryland Theodore J. Cicero, Ph.D. Washington University School of Medicine St Louis, Missouri Sidney Cohen, M.D Los Angeles, California Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute San Francisco, California Denise Kandel, Ph.D. College of Physicians and Surgeons of Columbia University New York, New York Herbert Kleber, M.D.
    [Show full text]
  • The NIDA CTN New England Consortium CTN New Englander Newsletter
    The NIDA CTN New England Consortium CTN New Englander newsletter Winter 2014 Volume 4, Issue 1 Winter 2014 Study Updates CTN-0047 Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED). Study results were shared with the participating sites on Octo- ber 30, 2013. CTN-0049 Project HOPE. Study recruitment & enrollment complete! This study is being conducted locally at Boston University-Boston Medical Center. Research staff affiliated with the Boston Medical Center’s Center for Infectious Diseases are conducting the study. Boston Medical Center started recruiting and enrolling study partici- IN THIS ISSUE pants in August 2012. The BU Medical Center site randomized the 800th par- ticipant in the study on January 30, 2014. As of February 2, 2014, 801 were Node News 1 randomized into the study overall with 94 randomized/enrolled at the BU Medi- Protocol Updates cal Center site. Treatment exposure remains high at 84% and the site is at 100% for the availability of primary outcome data trial performance metric. News from Field 2 CTN-0050 START Follow-Up Study. Lead Investigator, Yih-Ing Hser is conducting a long Research News term follow-up of participants from the original START protocol (CTN 0027). Two sites from Publications, 3 the former New England Node, Connecticut Counseling Centers and Hartford Dispensary Presentations and participated in CTN0027. The Hartford Dispensary and the research team from the Yale Upcoming Meetings RRTC are participating in CTN 0050. As of Sunday January 12, 2014, 130 participants have been enrolled from Harford Dispensary and 95 participants have been recruited from the Connecticut Counseling Center and have achieved high rates for the availability of primary outcome data: 100% (Hartford Dispensary) and 99% (CT Counseling Ctr.).
    [Show full text]
  • Mary Jeanne Kreek, MD
    The Modern Science of Addiction Mary Jeanne Kreek, M.D. Patrick E. and Beatrice M. Haggerty Professor Head of Laboratory The Laboratory of the Biology of Addictive Diseases The Rockefeller University Senior Physician, The Rockefeller University Hospital Science Board – Food and Drug Administration Silver Spring, Maryland March 1, 2016 Funded primarily by NIH-NIDA (P50-05130), The Adelson Medical Research Foundation, NIH-NCRR (RUH – Dr B. Coller) Prevalence of Drug Abuse in United States and Vulnerability to Develop Addictions National Household Survey and Related Surveys – 2007 – 2013 Alcohol Use – ever ~ 260 million Alcoholism ~ 16.5 million Marijuana Use – ever ~ 104 million Marijuana Daily Use ~ 5.7 million Cocaine Use – ever ~ 45.6 million Cocaine Addiction ~ 2 to 3 million Heroin Use – ever ~ 5.7 million Heroin Addiction ~ 1 million Illicit Use of Opiate Medication – ever ~ 37.1 million (i.e., 14.2% of the population 12 and over)* Development of Addiction After Self Exposure (meta-analyses) Alcoholism, Cocaine, Marijuana Addictions ~ 1 in 8 to 1 in 15 Heroin Addiction ~ 1 in 3 to 1 in 5 * 2007 National Survey on Drug Use and Health SAMHSA National Survey on Drug Use and Health, 2012; NIDA Monitoring the Future 2014; Others, 2007-2016 Number of Unintentional Drug Overdose Deaths Involving Prescription Opiates, Heroin, and Cocaine (United States, 1999-2007) and Rate of Heroin Overdose Deaths (2002-13) More than 3 people die every hour in the United States from illicit opiate overdose (2014). (T Frieden, Center for Disease Control and Prevention, 2015) 1.9 people die every day from heroin overdoses in New York City.
    [Show full text]
  • Methadone; the Drug and Its Therapeutic Uses in the Treatment of Addiction
    DOCUMENT RESUME BD 099 723 CG 009 315 AUTHOR Gamage, James R.; Zerkin, E. Lief TITLE Methadone; The Drug and Its Therapeutic Uses In the Treatment of Addiction. Series 31, No. 1. INSTITUTION National Inst. on Drug Abuse (DHEV/PHS), Rockville, Md. National Clearinghouse for Drug Abuse Information.; Student Association for the Study of Hallucinogens, Biloit, Nis. REPORT NO DHEW-ADM-74-126; Ser-31-1 PUB DATE Jul 74 NOT? 22p. AVAILABLE FROM National Clearinghouse for Drug Abuse Information, P.O. Box 1908, Rockville, Maryland20850 EDPS PRICE MR-S0.75 HC-S1.50 PLUS POSTAGE DESCRIPTORS *Drug Abuse; *Drug Education; *Drug Therapy; *Government Publications; Health Personnel; *Information Dissemination; Research ABSTRACT This fact sheet from the National Clearinghousefor Drug Abuse Information discusses methadone, atherapeutic drug for the treatment of narcotic addiction. It reviews thepharmacology of the drug as well as physiological andpsychological effects, patterns of use, and adverse effects (toxicity andpoisoning). It examines the success rates of inpatient andambulatory detoxification programs, and, in addition, establishes many differingviewpoints on the success of methadonemaintenance. Generally, detoxification programs have not been overly promising, andmaintenance programs have varied in their success. The report presentsnegative opinions about the use of methadone, ranging from cautious criticism tototal opposition, iv addition to a bibliography. (Author/PC) SEI 2 41974 i 01100111011411OP NOALTO. 110OCAT II ~NW SIATOOOr flamingOP ISOUCATiON DEMO gee.% pp< mai sitsA5 SOS Outf 0 I soCtt RECIMIFO0600 11fade TM Nes., OROodAtogoi ow et POW leOE eflits paoPOatONS MIS *Wok "OfOOP** JULY 1974 SERIES 31, NO.1 staled* 00 41101 SOO Of SOW Of KIMSigtrsokah goucastiNii Knit KietOs PCS My The National Clearinghouse for Drug Abuse Information recognizes the need for clarifying some of the more complex issues in drug abuse oy gathering the significant research findings on each subject and developing fact sheets on the problem.
    [Show full text]